What is Chardan Capital's Estimate for ARWR FY2025 Earnings?

Key Points

• Chardan Capital has revised its FY2025 earnings estimate for Arrowhead Pharmaceuticals to ($0.16) per share, significantly improving from the previous estimate of ($1.27).
• The company has a current consensus rating of Moderate Buy among analysts, with a price target averaging $43.14 despite some firms adjusting their targets in recent reports.
• Arrowhead Pharmaceuticals has seen increased institutional interest, with notable stakes raised by several hedge funds, indicating a growing confidence in the company's prospects.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Equities researchers at Chardan Capital increased their FY2025 earnings estimates for Arrowhead Pharmaceuticals in a note issued to investors on Monday, August 11th. Chardan Capital analyst K. Nakae now anticipates that the biotechnology company will post earnings per share of ($0.16) for the year, up from their prior estimate of ($1.27). Chardan Capital has a "Buy" rating and a $60.00 price objective on the stock. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.42) per share. Chardan Capital also issued estimates for Arrowhead Pharmaceuticals' FY2026 earnings at ($3.97) EPS.

Other equities analysts have also recently issued reports about the stock. B. Riley raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday. TD Cowen upgraded shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, July 28th. Royal Bank Of Canada decreased their target price on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th. Citigroup decreased their target price on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. Finally, HC Wainwright restated a "buy" rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 20th. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.14.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock traded down $1.65 during trading on Thursday, reaching $18.34. The company's stock had a trading volume of 957,751 shares, compared to its average volume of 1,893,335. The company has a 50-day moving average price of $16.59 and a two-hundred day moving average price of $15.95. The firm has a market cap of $2.54 billion, a PE ratio of -14.30 and a beta of 0.94. Arrowhead Pharmaceuticals has a fifty-two week low of $9.57 and a fifty-two week high of $27.34. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.39.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The firm had revenue of $27.77 million for the quarter, compared to analyst estimates of $29.01 million. During the same quarter last year, the firm earned ($1.38) earnings per share.

Institutional Trading of Arrowhead Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ARWR. Daiwa Securities Group Inc. lifted its stake in Arrowhead Pharmaceuticals by 883.3% during the second quarter. Daiwa Securities Group Inc. now owns 4,189 shares of the biotechnology company's stock worth $66,000 after purchasing an additional 3,763 shares during the last quarter. WINTON GROUP Ltd bought a new position in Arrowhead Pharmaceuticals during the second quarter worth $660,000. Pale Fire Capital SE lifted its stake in Arrowhead Pharmaceuticals by 11.0% in the second quarter. Pale Fire Capital SE now owns 13,571 shares of the biotechnology company's stock valued at $214,000 after buying an additional 1,350 shares during the last quarter. Cerity Partners LLC lifted its stake in Arrowhead Pharmaceuticals by 43.2% in the second quarter. Cerity Partners LLC now owns 15,863 shares of the biotechnology company's stock valued at $251,000 after buying an additional 4,785 shares during the last quarter. Finally, Tema Etfs LLC lifted its stake in Arrowhead Pharmaceuticals by 18.3% in the second quarter. Tema Etfs LLC now owns 35,359 shares of the biotechnology company's stock valued at $559,000 after buying an additional 5,466 shares during the last quarter. Institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.